The global COPD and asthma devices market is anticipated to grow at a considerable CAGR of 9.7% during the forecast period. Several government initiatives have been taken in China to spread awareness for COPD and asthma treatment. Chinese Alliance for Respiratory Disease in Primary Care (CARDPC) was founded in 2015 to solve the problems of the management system of respiratory disease in primary care and also to optimize the capability building of primary care physicians. During the end of 2019, the branches of CARDPC spread respectively in 29 out of 34 provinces. The organization holds annual conferences to spread awareness of asthma and COPD. The organization also set up the ‘Song Qingling Excellent Physicians InPrimary Award’ for primary care physicians to manage respiratory disease. Till 2021 CARDPC has set up more than 200 sessions in every city in China.
Browse the full report description “Global COPD and Asthma Devices Market Size, Share & Trends Analysis by Product type (Inhaler, Nebulizer, Humidifier And Dehumidifier, Respiratory Mask, Oxygen Concentrator), by End-User (Hospitals, Home Care) ForecastPeriod (2022-2028)” at https://www.omrglobal.com/industry-reports/copd-and-asthma-devices-market
Furthermore, Global Initative for Asthma organizes world asthma day on May 4 to raise the awareness of asthma globally. The theme for World Asthma Day 2021 was Uncovering Asthma Misconceptions to address the common myths associated with asthma.
The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launches, and product innovation to remain competitive in the marketplace. For instance, in April 2019, Boehringer Ingelheim completed the investment of 126.6 million, to expand the Respimat production operation at its sites in Dortmund and Ingelheim. This volume of investment and further development of Respimat illustrates the company's long-lasting commitment to solve the respiratory system related issues. The following expansion will be able to cure the people with respiratory diseases in other European countries as well such as Germany. In April 2019, Circassia Group PLC announced that the US Food and Drug Administration (FDA) had approved Duaklir for the treatment of chronic obstructive pulmonary disease (COPD). The following approval is based upon three Phase 3 studies including ACLIFORM, AUGMENT, and AMPLIFY positive results. With this approval, Duaklir will be able to make a significant contribution towards the treatment of COPD along with guidelines recommended by LAMA and LABA therapy.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape-3M Co., AstraZeneca PLC, Becton Dickinson & Co., Boehringer Ingelheim International GmbH, and Teva Pharmaceuticals Industries Ltd. among others.
Key questions addressed by the report
oDeviation from the pre-COVID-19 forecast
oMost affected region and segment
Global COPD and Asthma DevicesMarket Report Segment
By Product Type
By End-User
Global COPD and Asthma DevicesMarket Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/copd-and-asthma-devices-market